Arrhythmias & electrophysiology
Rationale and design of the NODE-303 study: evaluating the safety of symptom-prompted, self-administered etripamil for paroxysmal supraventricular tachycardia episodes in real-world settings
Study context
- Population
- Patients with paroxysmal supraventricular tachycardia (PSVT), real-world settings
- Primary endpoint
- Safety of symptom-prompted, self-administered etripamil for multiple PSVT episodes without test dosing (treatment-emergent AEs within 24 hours after administration)
Methodological detailsSecondary endpoints: efficacy (time to conversion to sinus rhythm within 30 and 60 minutes; proportion converting at 3, 5, 10, 20, 30 and 60 minutes) and disease burden (patient-reported outcomes)
- Secondary endpoints: efficacy (time to conversion to sinus rhythm within 30 and 60 minutes; proportion converting at 3, 5, 10, 20, 30 and 60 minutes) and disease burden (patient-reported outcomes)
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Rationale and design of the NODE-303 study: evaluating the safety of symptom-prompted, self-administered etripamil for paroxysmal supraventricular tachycardia episodes in real-world settings. Am Heart J. Published 22 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →